Cabotegravir (GSK-1265744) sodium 一种具有口服活性且长效的HIV 整合酶 (HIV integrase) 抑制剂,也是有机阴离子转运蛋白 1/3 (OAT1/OAT3) 抑制剂,对 HIVADA、OAT3 和 OAT1 的 IC50 分别为 2.5 nM、0.41 μM 和 0.81 μM。Cabotegravir sodium 主要由尿苷二磷酸葡萄糖醛酸转移酶 (UGT) 1A1 代谢,与其他抗逆转录病毒药物 (ARVs) 相互作用的可能性较低。Cabotegravir sodium 可用于艾滋病 (AIDS) 的研究。
Cas No. | 1051375-13-3 |
别名 | 卡博特韦钠; GSK-1265744 sodium; S/GSK1265744 sodium |
分子式 | C19H16F2N3NaO5 |
分子量 | 427.33 |
溶解度 | DMSO : 6.9 mg/mL (16.15 mM; ultrasonic and warming and heat to 60°C) |
储存条件 | 4°C, away from moisture |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Cabotegravir (GSK-1265744) sodium is a orally active and long-actingHIV integraseinhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor withIC50values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs). Cabotegravir sodium can be used to research AIDS[1][2]. |